Skip to main content
Top
Published in: Supportive Care in Cancer 3/2024

Open Access 01-03-2024 | Cytostatic Therapy | Research

Continuous timely monitoring of core temperature with two wearable devices in pediatric patients undergoing chemotherapy for cancer – a comparison study

Authors: Christa Koenig, Roland A. Ammann, Christine Schneider, Johanna Wyss, Jochen Roessler, Eva Brack

Published in: Supportive Care in Cancer | Issue 3/2024

Login to get access

Abstract

Purpose

Pediatric patients with cancer often develop chemotherapy-induced fever in neutropenia (FN), requiring emergency broad-spectrum antibiotics. Continuous temperature monitoring can lead to earlier FN detection and therapy with improved outcomes. We aimed to compare the feasibility of continuous core temperature monitoring with timely data availability between two wearable devices (WDs) in pediatric oncology patients undergoing chemotherapy.

Methods

In this prospective observational two-center study, 20 patients (median age: 8 years) undergoing chemotherapy simultaneously wore two WDs (CORE®, Everion®) for 14 days. The predefined goal was core temperature recorded in sufficient quality and available within ≤ 30 min during ≥ 18/24 h for ≥ 7/14 days in more than 15 patients.

Results

More patients reached the goal with CORE® (n = 13) versus Everion® (n = 3) (difference, 50% p < 0.001). After correcting for the transmission bottleneck caused by two WDs transmitting via one gateway, these numbers increased (n = 15 versus n = 14; difference, 5%; p = 0.69). CORE® measurements corresponded better to ear temperatures (n = 528; mean bias, − 0.07 °C; mean absolute difference, 0.35 °C) than Everion® measurements (n = 532; − 1.06 °C; 1.10 °C). Acceptance rates for the WDs were 95% for CORE® and 89% for Everion®.

Conclusion

The CORE® fulfilled the predefined feasibility criterion (15 of 20 patients) after correction for transmission bottleneck, and the Everion® nearly fulfilled it. Continuous core temperature recording of good quality and with timely data availability was feasible from preschool to adolescent patients undergoing chemotherapy for cancer. These results encourage the design of randomized controlled trials on continuously monitored core temperature in pediatric patients.
Trial registration.
ClinicalTrials.gov (NCT04914702) on June 7, 2021.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lehrnbecher T, Robinson PD, Ammann RA et al (2023) Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 Update. J Clin Oncol 20;41(9):1774–1785. https://doi.org/10.1200/JCO.22.02224 Lehrnbecher T, Robinson PD, Ammann RA et al (2023) Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 Update. J Clin Oncol 20;41(9):1774–1785. https://​doi.​org/​10.​1200/​JCO.​22.​02224
4.
go back to reference Koenig C, Bodmer N, Agyeman PKA, et al (2020) 39.0°C versus 38.5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health 4(7):495–502. https://doi.org/10.1016/S2352-4642(20)30092-4 Koenig C, Bodmer N, Agyeman PKA, et al (2020) 39.0°C versus 38.5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health 4(7):495–502. https://​doi.​org/​10.​1016/​S2352-4642(20)30092-4
20.
go back to reference Altman DG (1991) Practical statistics for medical research. Chapman & Hall, London, United Kingdom Altman DG (1991) Practical statistics for medical research. Chapman & Hall, London, United Kingdom
Metadata
Title
Continuous timely monitoring of core temperature with two wearable devices in pediatric patients undergoing chemotherapy for cancer – a comparison study
Authors
Christa Koenig
Roland A. Ammann
Christine Schneider
Johanna Wyss
Jochen Roessler
Eva Brack
Publication date
01-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 3/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08366-w

Other articles of this Issue 3/2024

Supportive Care in Cancer 3/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine